Skip to main content

Genomic Data Analysis and Interpretation Market to See Wonderful Rise during 2020-2030 with High CAGR Growth

 Healthcare experts at BIS have found genomic data analysis and interpretation industry to be one of the most rapidly evolving and dynamic markets and the global market for Genomic data analysis and interpretation is predicted to grow at a CAGR of 10.21% over the forecast period of 2020-2030. The market is driven by certain factors, which include decreasing cost of sequencing, global increase in cancer prevalence, and increasing number of population genomics initiative, among others, are fueling the growth of the global genomic data analysis and interpretation market.

The market is favored by the developments in the field of genomics and bioinformatics. Currently, the genomic data analysis and interpretation industry is witnessing an upsurge due to the growing number of genomic research initiatives being undertaken by the developing and developed countries coupled with the decreasing cost of sequencing, resulting in the high demand for software solutions for genomic data analysis. Additionally, high adoption of sequencing instruments by the researchers and clinicians, coupled with the growing prevalence of complex diseases, such as cancer, are some of the critical factors expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust genomic data analysis software solutions for a wide range of clinical applications to support clinicians in conducting an in-depth analysis.

The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of reliable genomic software solutions for data analysis, further aiding clinicians to offer precision oncology treatments. Due to the presence of a diverse product portfolio and intense market penetration, Thermo Fisher Scientific Inc. has been a pioneer in this field and has been a significant competitor in this market.

On the basis of region, North America holds the largest share of the genomic data analysis and interpretation market due to high infusion of funding from the government organizations for conducting research on genomics and bioinformatics, rising prevalence of cancer, growing awareness about precision medicine, and decreasing cost of sequencing, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.

The current market assessment has considered information provided by key opinion leaders in the market, from both supply and demand sides. Although manufacturers have witnessed low-scale losses due to decreased demand, the losses incurred for the first two quarters of FY2020-2021 are anticipated to be compensated by higher demands in the following two quarters. However, the industry is still expected to be impacted significantly during the period between 2020 and 2022.

Request a Sample - https://bisresearch.com/requestsample?id=1051&type=download



Comments

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: •     Industry Analysis    ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...